An assessment of the safety and efficacy of sibutramine, an anti‐obesity drug with a novel mechanism of action

@article{Nisoli2000AnAO,
  title={An assessment of the safety and efficacy of sibutramine, an anti‐obesity drug with a novel mechanism of action},
  author={Enzo Nisoli and M O Carruba},
  journal={Obesity Reviews},
  year={2000},
  volume={1}
}
Sibutramine is a combined serotonin(5‐HT) and noradrenaline (NA)re‐uptake inhibitor. Sibutramine works predominantly through its two pharmacologically active metabolites (i.e. primary and secondary amines) which induce marked weight loss by affecting both food intake and energy expenditure. It is able to enhance the physiological process of satiety, and to stimulate thermogenesis, increasing the efferent sympathetic activity to thermogenically active brown fat. There is a dose‐related reduction… 
A Benefit-Risk Assessment of Sibutramine in the Management of Obesity
TLDR
Results from mainly small trials showed that sibutramine produced more favourable outcomes in terms of loss of fat mass, reduction in body mass index and loss of ≥5–10% of initial bodyweight.
Cardiovascular Risk-Benefit Profile of Sibutramine
  • A. Scheen
  • Medicine, Biology
    American journal of cardiovascular drugs : drugs, devices, and other interventions
  • 2010
TLDR
Concern still persists about the safety profile of sibutramine regarding cardiovascular outcomes, and the drug should not be prescribed for overweight/obese patients with a high cardiovascular risk profile, according to the final results of SCOUT.
SIBUTRAMINE AND CASE REPORTS OF CVD ADVERSE EVENTS
TLDR
The recent Sibutramine Cardiovascular Outcomes Trial (SCOUT) confirmed that subjects with preexisting cardiovascular disease on long-term treatment with sibutamine had a significantly increased risk for nonfatal myocardial infarction and nonf fatal stroke, but not cardiovascular death or all-cause mortality.
Sibutramine on Cardiovascular Outcome
TLDR
The recent Sibutramine Cardiovascular Outcomes Trial (SCOUT) confirmed that subjects with preexisting cardiovascular disease (CVD) on long-term treatment with sibutamine had a significantly increased risk for nonfatal myocardial infarction and nonf fatal stroke, but not cardiovascular death or all-cause mortality.
Effects of isolated or combined exposure to sibutramine and rosuvastatin on reproductive parameters of adult male rats
TLDR
Given the greater reproductive efficiency of rodents, the results obtained in the present study raise concern regarding possible fertility impairment in men taking statins and SNRI drugs.
Anti-Obesity Drugs: A Review about Their Effects and Safety
TLDR
Orlistat is presently the only available choice for the treatment of obesity because of its safety for cardiovascular events and positive effects on diabetic control.
Use of sibutramine an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: A placebo-controlled study
TLDR
The findings suggest sibutramine is an effective medication in the treatment of binge-eating disorders and is well tolerated, and addresses the 3 main goals in the Treatment of Binge-eating disorder: reducing the frequency of binge eating, promoting and maintaining weight loss, and treating the comorbid psychiatric conditions.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 81 REFERENCES
Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
  • L. V. Van Gaal, M. Wauters, I. D. De Leeuw
  • Medicine, Biology
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • 1998
TLDR
Subcutaneous/visceral fat ratio was found to increase significantly under sibutramine treatment, indicating that relatively more visceral fat than subcutaneous fat is lost.
Sibutramine. A review of its contribution to the management of obesity.
TLDR
Obese patients with type 2 (non-insulin-dependent) diabetes or hypertension lost significantly more mean bodyweight with sibutramine than with placebo, although weight loss was less than that in obese patients without comorbidities, and concerns over potential pressor effects are reflected in the manufacturer's dosage and administration recommendations.
Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
  • M. Stock
  • Biology
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
  • 1997
TLDR
Dual effects of sibutramine on food intake and thermogenesis explain its anti-obesity effect in animals.
Thermogenic effects of sibutramine in humans.
TLDR
Sibutramine caused a significant increase in both EE and satiety, which may both contribute to its weight-reducing properties.
Sibutramine produces dose-related weight loss.
TLDR
Sibutramine administered once daily for 24 weeks in the weight loss phase of treatment for uncomplicated obesity produced dose-related weight loss and was well tolerated, including small mean increases in blood pressure and heart rate.
Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study
TLDR
Doses of 10 mg and 15”mg once daily were shown to be similarly effective, well tolerated and significantly more effective than the placebo, and dose-related weight loss with sibutramine treatment for up to 12 weeks in obese patients is demonstrated.
Thermogenic effects of sibutramine and its metabolites
The thermogenic activity of the serotonin and noradrenaline reuptake inhibitor sibutramine (BTS 54524; Reductil) was investigated by measuring oxygen consumption (VO2) in rats treated with
Sibutramine--a review of clinical efficacy.
  • M. Lean
  • Medicine
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity
  • 1997
TLDR
Sibutramine-induced weight loss has been found to be accompanied by a significant reduction in waist/hip ratio, and decreases in plasma triglycerides, total cholesterol and low density lipoprotein (LDL) cholesterol, in patients with type II diabetes.
The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction
TLDR
The weight reducing effect of sibutramine in humans is caused by a dual mechanism: reduction of energy intake by increasing satiety and decreasing hunger and prevention of the decline in EE that follows weight loss.
The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females
TLDR
Sibutramine limits the decline in REE associated with weight loss, equivalent to about 100 kcal/d, which could allow greater numbers of people to maintain a greater degree of weight loss.
...
1
2
3
4
5
...